BTIG Rates iRhythm (IRTC) buy, $185 Price Target

BTIG analyst Marie Thibault reiterates a buy rating on iRhythm with a $185 price target, a 62.78% upside from the current price.

By TradeTexts Research Desk · Published Jun 13, 2026, 2:09 AM EDT · Updated Jun 15, 2026, 10:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

BTIG rated iRhythm Holdings, Inc. ($IRTC) "buy" with a $185 price target on June 10, 2026.

Since the rating, $IRTC is down 10.7% after 1 week, up 1.9% after 1 month and down 4.6% to date (from the $113.94 close on Jun 10, 2026).

IRTC iRhythm Holdings, Inc.

$108.66 -37.99% year to date

Daily close · Oct 16, 2026

Key Points

BTIG analyst Marie Thibault reiterated a buy rating on iRhythm Holdings, Inc. with a $185 price target on June 10, 2026.
BTIG's $185 price target implies 62.78% upside from iRhythm Holdings, Inc.'s ($IRTC) current $113.65 share price.
Shares of NasdaqGS:IRTC traded near $113.65, with a market cap of about $3.73 billion and a forward P/E ratio of 108.1.
Insider transactions included both buying and selling, with recent buys by executives like CEO Quentin Blackford.

Get $IRTC trade alerts by text

We text you when insiders, Congress or big funds trade $IRTC. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated iRhythm Holdings, Inc. alert may contain errors. Disclosures

On June 10, 2026, BTIG analyst Marie Thibault reiterated a buy rating for iRhythm Holdings, Inc. (NasdaqGS: IRTC), maintaining a price target of $185. This comes as shares of the digital healthcare company traded around $113.65.

Analysts Set New Price Targets

Thibault's reiteration of a buy rating at a target of $185 highlights continued confidence in iRhythm. Just days earlier, Canaccord Genuity maintained its buy rating with a $152 target, and B of A Securities echoed a similar sentiment with a $180 target. Citigroup, JP Morgan, and Wells Fargo have all recently maintained buy ratings, underscoring a strong consensus among analysts.

Other Institutional Activity in iRhythm Holdings

Institutional activity has been bustling around iRhythm. Tudor Investment Corp Et Al added a substantial 20 million shares, bringing its total to the same number, valued at about $21.97 million. BlackRock, Inc. slightly trimmed its position by 72,484 shares, ending with over 2.74 million shares worth approximately $323.55 million. Meanwhile, RTW Investments, LP increased its stake by 486,510 shares, now holding around 1.67 million shares valued at $196.92 million.

iRhythm Holdings, Inc. Stock Up 4.0%

Shares of iRhythm Holdings, Inc. are currently trading near $113.65. The company, with a market cap of approximately $3.73 billion, has a forward P/E ratio of 108.1, indicating high expected growth. Its stock has fluctuated between $101.75 and $212 over the past 52 weeks. The company's 50-day moving average is $117.21, while the 200-day moving average stands at $151.76.

12-month forecast

$IRTC price target

iRhythm Holdings, Inc. daily closes and this analyst's $185 target. Not advice.

Insider Buying and Selling at iRhythm Holdings, Inc.

Recent insider activity at iRhythm included both buying and selling. On June 2, 2026, Chief Accounting Officer Marc Wade Rosenbaum sold 729 shares at an average price of $108.19. EVP and Chief Risk Officer Sumi Shrishrimal also sold 1,716 shares at the same price. On May 29, several executives, including CEO Quentin Blackford, purchased shares at $96.82, indicating some internal confidence in the stock's future.

About iRhythm Holdings, Inc.

Based in San Francisco, iRhythm Holdings, Inc. is a digital healthcare company specializing in device-based technology for ambulatory cardiac monitoring. Its flagship Zio services help diagnose arrhythmias through long-term and short-term monitoring. The company is led by CEO Quentin Blackford and employs about 2,400 people.

Bottom Line

BTIG's reiterated buy rating and the $185 price target for iRhythm Holdings, Inc. reflect continued analyst confidence in the company. With its shares trading around $113.65, iRhythm remains a focal point for institutional investors and insiders alike. Remember, 13F filings reflect past holdings and may not indicate current positions.